Looking Long on SGEN
CD20 v. CD30: Will SeaGen's Adcetris Be the Next Rituxan?
By Trista Morrison
With this month's FDA approval of Adcetris (brentuximab vedotin), Seattle Genetics Inc. can lay claim to many firsts: first commercial product for the Bothell, Wash.-based biotech, first new drug for Hodgkin lymphoma patients in more than 30 years, first antibody-drug conjugate to gain FDA approval and first anti-CD30-targeted therapy approved. (See BioWorld Today, Aug. 22, 2011.)